Safety, tolerability, and efficacy of orally administered cannabinoids in MS
Cannabinoids are found in the Cannabis plant and its cannabis sativa extract is said to have an anti-inflammatory effect on animal cells. Medical marijuana has been used in the past for treating ms related symptoms like spasticity and pain. This paper investigates the safety, tolerability, and efficacy of oral tetrahydrocannabinol (THC) and Cannabidiol (CBD’s) on patients with multiple sclerosis (MS).
Here is the full scientific article if you wish to download it.
Both drugs were safe in this study, but adverse events were more likely when patients were treated with CBD. Long-term effects of spasticity were improved, however, both THC and CBD treatment worsened the participant’s spatial awareness. THC is absorbed reasonably well from the gut, but the process is slow, with an extensive range between and within individuals. Animal studies have demonstrated that CBD administration gets in the way of drug metabolism in the liver.
Evidence suggests that cannabinoids can relieve muscle spasticity and other symptoms in MS. Discovery of both the cannabinoid receptors, present throughout the nervous system and the peripheral immune system, and the endogenous cannabinoid system has made this study more popular among scientists. Many patients with MS are already using cannabis to alleviate their symptoms.
The majority of patients experienced unpleasant side effects. A previous study has illustrated that cannabinoids can reduce spasticity in mice with chronic relapsing experimental autoimmune encephalomyelitis. In another study, 10 people with MS symptoms and 10 people without it smoked cannabis. Some patients noted an improvement, however, posture and balance in both of these types of patients were impaired. It’s clear that more studies need to be done.